Work

Nucleoside-modified mRNA encoding HSV-2 glycoproteins C, D, and E prevents clinical and subclinical genital herpes

Year: 2019

Type: article

Abstract: T cell responses, and T follicular helper and germinal center B cell responses. The trivalent nucleoside-modified mRNA-LNP vaccine is a promising candidate for human trials.

Source: Science Immunology

DOI: 10.1126/sciimmunol.aaw7083

Authors: Sita Awasthi, Lauren M. Hook, Norbert Pardi, Fushan Wang, Arpita Myles, Michael P. Cancro, Gary H. Cohen, Drew Weissman, Harvey M. Friedman

Institution: University of Pennsylvania

Language: English

Topic: Herpesvirus Infections and Treatments

Subfield: Epidemiology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: Bill and Melinda Gates Foundation, Takeda Science Foundation, National Institute of Allergy and Infectious Diseases

Awards: Functions of HSV glycoproteins in virus entry and the humoral immune response, HSV-2 immune evasion as a virulence factor, G3070653503, G3574387646, G3765360276, RNA delivery for dendritic cell HIV antigen presentation, G4554281539, Nucleoside modified mRNA based HIV vaccine, G7071116592, G743408110, G7470945164, G829126091, Nucleoside-modified mRNA vaccine for prevention and treatment of genital herpes, Penn Center for AIDS Research, G92454453

OpenAlex ID: W2973308780

FWCI: 10.84

Cites: 59

Cited by: 119

Related to: 10